Skip to main content

Table 1 Patient demographics of stage IV NSCLC cohort

From: Circulating tumor cells as a response monitor in stage IV non-small cell lung cancer

  NSCLC Kinetics
Cohort (n = 81) Cohort (n = 25)
Age (years), median (range) 61 (33–90) 64 (39–78)
WBC count (e6), median (range) 6.8 (0.8–29.9) 8.1 (3.5–19.9)
Sex, n (%)
 Female 37 (45.7) 11 (44.0)
 Male 32 (39.5) 13 (52.0)
 N/A 12 (14.8) 1 (4.0)
Histologll, n (%)
 ACA 66 (81.5) 20 (80.0)
 Sec 8 (9.9) 4 (16.0)
 LCC 1 (1.2)
 NOS 3 (3.7) 1 (4.0)
 N/A 3 (3.7)
Location of primary mass, n (%)
 RUL 26 (32.1) 7 (28.0)
 LUL 22 (27.2) 8 (30.0)
 RML 3 (3.7)
 RLL 13 (16.0) 3 (12.0)
 LLL 12 (14.8) 2 (8.0)
 R Hilum 1 (1.2) 1 (4.0)
 None 2 (2.5) 1 (4.0)
 N/A 2 (2.5) 3 (12.0)
Stage, n (%)
 IVA 18 (22.2) 6 (24.0)
 IVB 40 (49.4) 18 (72.0)
Recurrent metastatic   1 (4.0)
 IVA 5 (6.2)
 IVB 13 (16.0)
 N/A 5 (6.2)
Therpay, n (%)
 Entering 1st line 75 (92.6) 24 (96.0)
  Crizotinib 1 (1.2) 1 (4.0)
  Erlotinib 9 (11.1) 2 (8.0)
  Platinum2 35 (43.2) 14 (56.0)
  Platinum2 + erlotinib 1 (1.2)
  Platinum3 28 (34.6) 7 (28.0)
  Pemetrexed 1 (1.2)
 Entering 2nd line 48 (59.3) 12 (48.0)
  Crizotinib 2 (2.5) 1 (4.0)
  Docetaxel 1 (1.2)
  Erlotinib 37 (45.7) 8 (32.0)
  Navelbine 1 (1.2)
  Platinum2 3 (3.7) 2 (8.0)
  Platinum3 3 (3.7) 1 (4.0)
  Taxotere 1 (1.2)
 Entering 3rd line 21 (25.9) 5 (20.0)
  Crizotinib 1 (1.2)
  Docetaxel 1 (1.2)
  Erlotinib 10 (12.3) 4 (16.0)
  Gemcitabine 1 (1.2)
  Navelbine 1 (1.2)
  Platinum2 5 (6.2) 1 (4.0)
  Platinum3 1 (1.2)
  Pemetrexed 1 (1.2)
 Entering 4th line 18 (22.2) 2 (8.0)
  Crizotinib 1 (1.2)
  Erlotinib 4 (4.9) 1 (4.0)
  Navelbine 10 (12.3) 1 (4.0)
  Platinum2 2 (2.5)
  Other 1 (1.2)
 Entering 5th line 5 (6.2)
  Navelbine 4 (4.9)
  Platinum2 1 (1.2)
 Entering 6th line
  Erlotinib 2 (2.5)
 Entering 7th line
  Navelbine 1 (1.2)
 Entering 8th line
  Etoposide 1 (1.2)
Site of secondary metastatic lesions, n (%)
 Adrenal gland 8 (9.9) 4 (16.0)
 Bone 32 (39.5) 10 (40.0)
 Brain 21 (25.9) 6 (24.0)
 Liver 14 (17.3) 3 (12.0)
 Pleura 29 (35.8) 6 (24.0)
 Lung 28 (34.6) 8 (32.0)
 Kidney 1 (1.2)
 Pericardium 3 (3.7)
 Muscle 1 (1.2) 1 (4.0)
 Skin 2 (2.5) 1 (4.0)
 Axillary LN 3 (3.7)
 Spleen 1 (1.2)
Number of distant metastatic lesions, n (%)
 0 23 (28.4) 8 (32.0)
 1 37 (45.7) 11 (44.0)
 2 19 (23.5) 3 (12.0)
 3 20 (2.5) 3 (12.0)
Mutation, n(%)
 ALK
  Positive 2 (2.5) 1 (4.0)
  Negative 3 (3.7) 2 (8.0)
 KRAS
  WT 12 (14.8) 3 (12.0)
  Mutant 6 (7.4) 4 (16.0)
 EGFR
  WT 10 (12.3)
  Mutant 7 (8.6)
  1. ACA: adenocarcinoma; SCC: squamous cell carcinoma; LCC: Large-cell carcinoma; NOS: Not otherwise specified; RUL: right upper lobe; LUL: left upper lobe; RML: right middle lobe; RLL: right lower lobe; LLL: left lower lobe; LN: lymph node; N/A: data not available